Literature DB >> 2077352

Molecular evolution of ubiquitous beta-lactamases towards extended-spectrum enzymes active against newer beta-lactam antibiotics.

E Collatz1, R Labia, L Gutmann.   

Abstract

Production of beta-lactamases, and of the plasmid-encoded TEM- and SHV-type enzymes in particular, is the most common mechanism of resistance against beta-lactam antibiotics in Gram-negative bacteria. The two ubiquitous types of enzyme have a large spectrum of activity and preferentially hydrolyse the penicillins as well as some first- and second-generation cephalosporins. Recently, point mutations in the corresponding genes have been observed, apparently selected for, in the clinical setting, by originally 'beta-lactamase-stable' third-generation cephalosporins or by monobactams, which fall into the substrate range of the mutant or 'extended-spectrum' beta-lactamases. The point mutations are clustered in three areas, each adjacent to one of the seven evolutionarily conserved boxes described by Joris et al. (1988). The substituted amino acids at positions 102 (adjacent to the alpha-3 helix), 162 (adjacent to the alpha-7 helix) and 235, 236 and 237 (on the beta-3 strand) are located in close proximity to the active-site cavity and are thought to open up novel enzyme-substrate interactions, involving, in particular, the oxyimino moieties of the newer beta-lactam compounds.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2077352     DOI: 10.1111/j.1365-2958.1990.tb00537.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  15 in total

1.  Identification of amino acid substitutions that alter the substrate specificity of TEM-1 beta-lactamase.

Authors:  T Palzkill; D Botstein
Journal:  J Bacteriol       Date:  1992-08       Impact factor: 3.490

Review 2.  Catalytic properties of class A beta-lactamases: efficiency and diversity.

Authors:  A Matagne; J Lamotte-Brasseur; J M Frère
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

3.  Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations.

Authors:  R A Bonomo; J R Knox; S D Rudin; D M Shlaes
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.

Authors:  X Y Zhou; F Bordon; D Sirot; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

5.  Extended-spectrum beta-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals.

Authors:  M Quinteros; M Radice; N Gardella; M M Rodriguez; N Costa; D Korbenfeld; E Couto; G Gutkind
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

6.  Antibiotic-resistant soil bacteria in transgenic plant fields.

Authors:  Sandrine Demanèche; Hervé Sanguin; John Poté; Elisabeth Navarro; Dominique Bernillon; Patrick Mavingui; Walter Wildi; Timothy M Vogel; Pascal Simonet
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-21       Impact factor: 11.205

7.  Five independent combinations of mutations can result in low-affinity penicillin-binding protein 2x of Streptococcus pneumoniae.

Authors:  G Laible; R Hakenbeck
Journal:  J Bacteriol       Date:  1991-11       Impact factor: 3.490

8.  Mechanism of acyl transfer by the class A serine beta-lactamase of Streptomyces albus G.

Authors:  J Lamotte-Brasseur; G Dive; O Dideberg; P Charlier; J M Frère; J M Ghuysen
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

9.  Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6.

Authors:  T Naas; L Vandel; W Sougakoff; D M Livermore; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resistance to expanded-spectrum cephalosporins.

Authors:  T J Coffey; M Daniels; L K McDougal; C G Dowson; F C Tenover; B G Spratt
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.